{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"86.7","value":"33.3"},{"groupId":"OG001","lowerLimit":"23.1","upperLimit":"88.0","value":"55.6"},{"groupId":"OG002","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG003","lowerLimit":"7.9","upperLimit":"64.8","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors.\n\n* CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).\n* PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \\>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).\n* SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG000","title":"Part B Cohort B1"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG001","title":"Part B Cohort B2"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG002","title":"Part B Cohort B3"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG003","title":"Part B Cohort B5"}],"paramType":"NUMBER","populationDescription":"All participants in Part B who received at least one dose of the study drug and had evaluable data for this outcome. Per pre-specified statistical analysis plan, analysis was performed as per the study treatments received.","reportingStatus":"POSTED","timeFrame":"Date of first dose to measured progressive disease (Up to 25 Months)","title":"Percentage of Participants With DCR: Part B","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}